Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

← Back to Medmonitor

Medication Type: Obesity

Obesity

Saxenda^® (liraglutide) injection

Approval Date: Aug 2025

Note: First-Time Generic

A GLP-1 receptor antagonist, this drug is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or who are overweight with at least one weight-related comorbidity. This is the first generically available GLP-1 receptor agonist for the treatment of obesity.